Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
In May 2022, there is an International Regulatory and Pharmaceutical Industry (Innovation and Quality [IQ] Microphysiological Systems [MPS] Affiliate) Workshop on the standardization of complex in vitro models (CIVMs) in drug development. This manuscript summarizes the discussions and conclusions of this joint workshop organized and executed by the IQ MPS Affiliate and the United States Food and Drug Administration (FDA). A key objective of the workshop is to facilitate discussions around opportunities and/or needs for standardization of MPS and chart potential pathways to increase model utilization in the context of regulatory decision making. Participation in the workshop included 200 attendees from the FDA, IQ MPS Affiliate, and 26 global regulatory organizations and affiliated parties representing Europe, Japan, and Canada. It is agreed that understanding global perspectives regarding the readiness of CIVM/MPS models for regulatory decision making and potential pathways to gaining acceptance is useful to align on globally. The obstacles are currently too great to develop standards for every context of use (COU). Instead, it is suggested that a more tractable approach may be to think of broadly applicable standards that can be applied regardless of COU and/or organ system. Considerations and next steps for this effort are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The growing demand for qualified MPS and OoC models is driven by initiatives such as the IQ MPS Consortium (Tomlinson et al., 2024), which focuses on integrating these systems into industry workflows.”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Tomlinson et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
PDMS absorption of small molecules and consequences in microfluidic applications
Toepke, M. W., & Beebe, D. J. (2006) · Lab on a Chip · doi:10.1039/b612140c · Cited by 1,190
Fundamentals of microfluidic cell culture in controlled microenvironments
Young, E. W. K., & Beebe, D. J. (2010) · Chemical Society Reviews · doi:10.1039/b909900j · Cited by 615
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Coecke, S., Balls, M., Bowe, G., Davis, J., Gstraunthaler, G., Hartung, T., Hay, R., Merten, O.-W., Price, A., Schechtman, L., et al. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300313 · Cited by 371
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Bell, C. C., Dankers, A. C. A., Lauschke, V. M., Sison-Young, R., Jenkins, R., Rowe, C., Goldring, C. E., Park, K., Regan, S. L., Walker, T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx289 · Cited by 327
Grimstein, M., Yang, Y., Zhang, X., Grillo, J., Huang, S.-M., Zineh, I., & Wang, Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.033 · Cited by 317
Research works printed but not linked: 6
- Baran S. W., 2022, ALTEX, 39
- Wang X., 2022, ALTEX
- Ramsden D., 2022, ALTEX, 39, 273
- a)I. S. (R3) Vol. 2022 2020;
- b)I. S10 Vol. 2022 2014.
- FDA Vol. 2022 2022.
Cited by
Papamichail, L., Koch, L. S., Veerman, D., Broersen, K., & van der Meer, A. D. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1515340 · Cited by 120
Towards in vitro models for reducing or replacing the use of animals in drug testing
Stresser, D. M., Kopec, A. K., Hewitt, P., Hardwick, R. N., Van Vleet, T. R., Mahalingaiah, P. K. S., O’Connell, D., Jenkins, G. J., David, R., Graham, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01154-7 · Cited by 94
Self-citationApplication of new approach methodologies for nonclinical safety assessment of drug candidates
Beilmann, M., Adkins, K., Boonen, H. C. M., Hewitt, P. G., Hu, W., Mader, R., Moore, S., Rana, P., Steger‐Hartmann, T., Villenave, R., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01182-9 · Cited by 85
Self-citationOuédraogo, G., Alépée, N., Tan, B., & Roper, C. S. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105904 · Cited by 64
Fetal bovine serum: how to leave it behind in the pursuit of more reliable science
Weber, T., Malakpour‐Permlid, A., Chary, A., D’Alessandro, V., Haut, L., Seufert, S., Wenzel, E. V., Hickman, J. J., Bieback, K., Wiest, J., et al. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1612903 · Cited by 53
Metadata
- Authors
- Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., David, R., Delrue, N., Devine, P. J., Ford, K., Garcia, M. I., Gosset, J. R., Hewitt, P., Homan, K., Irrechukwu, O., Kopec, A. K., Liras, J. L., Mandlekar, S., Raczynski, A., Sadrieh, N., Sakatis, M. Z., Siegel, J., Sung, K., Sunyovszki, I., Van Vleet, T. R., Ekert, J. E., & Hardwick, R. N.
- Affiliations
- Pfizer (United States) (US)
- DMPK Oncology AstraZeneca Boston MA 02451 USA
- European Commission (BE)
- Federal Agency for Medicines and Health Products Brussels 1210 Belgium
- United States Food and Drug Administration (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- Genentech (US)
- Biogen (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- Organisation de Coopération et de Développement Economiques (FR)
- Bristol-Myers Squibb (United States) (US)
- Merck Healthcare KGaA, Darmstadt (Germany) (DE)
- Johnson & Johnson (United States) (US)
- Vertex Pharmaceuticals (United States) (US)
- Center for Biologics Evaluation and Research (US)
- AbbVie, Inc. North Chicago IL 60064 USA
- UCB Pharma Cambridge MA 02140 USA
- Corresponding author
- Tomlinson, Lindsay
- Ekert, Jason E.
- Hardwick, Rhiannon N.
- ORCID
- Tomlinson, Lindsay
- Ramsden, Diane
- Leite, Sofia Batista
- Beken, Sonja
- Bonzo, Jessica A.
- Brown, Paul
- Candarlioglu, Pelin L.
- Chan, Tom S.
- David, Rhiannon
- Ford, Kevin
- Garcia, Martha Iveth
- Hewitt, Philip
- Homan, Kimberly
- Irrechukwu, Onyi
- Kopec, Anna K.
- Liras, Jennifer L.
- Sadrieh, Nakissa
- Sakatis, Melanie Z.
- Siegel, Jeffrey
- Sung, Kyung
- Ekert, Jason E.
- Hardwick, Rhiannon N.
- Venue
- Advanced Biology
- Publisher
- Wiley
- Published
- 2023-10-09
- Volume
- 8
- Issue
- 8
- Pages
- e2300131-e2300131
- ISSN
- 2701-0198 (ISSN-L)
- OpenAlex
- W4387473497
- Cited by
- 33
- References
- 54
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 6 · 2023: 2
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Advanced Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Food Safety Authority
- U.S. Food and Drug Administration
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- microphysiological systems, standardization, regulatory decision-making, drug development, regulatory acceptance, context of use, FDA
- MeSH terms
- Drug Development, Drug Industry, Humans, United States, United States Food and Drug Administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development. https://app.cochat.ai/papers/10.1002/adbi.202300131
- The paper
- Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., David, R., Delrue, N., Devine, P. J., Ford, K., Garcia, M. I., Gosset, J. R., Hewitt, P., Homan, K., Irrechukwu, O., . . . Hardwick, R. N. (2024). Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development. Advanced Biology. https://doi.org/10.1002/adbi.202300131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.